Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.93
    -0.43 (-0.52%)
     
  • GOLD FUTURES

    2,331.90
    -10.20 (-0.44%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,364.67
    -1,830.78 (-3.44%)
     
  • CMC Crypto 200

    1,389.96
    -34.14 (-2.40%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Novartis AG wins approval to buy GSK cancer drugs with conditions

(Corrects name of inhibitor in paragraph two to MEK from MIK)

WASHINGTON, Feb 23 (Reuters) - Novartis AG (LSE: 0QLR.L - news) has won U.S. antitrust approval to buy GlaxoSmithKline (Other OTC: GLAXF - news) 's oncology drugs with conditions, the Federal Trade Commission said on Monday.

To win approval for the $16 billion deal, Novartis agreed to divest assets related to its BRAF and MEK inhibitor drugs, now in development to fight melanoma and other cancers, the agency said. (Reporting by Diane Bartz; Editing by Kevin Drawbaugh, Editing by Franklin Paul)